JAMES MAGNER, M.D.
Osteopathic Medicine at Field Dr, New Haven, CT

License number
Connecticut 36265
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
1022 Field Dr, New Haven, CT 06525
Phone
(475) 227-6740

Personal information

See more information about JAMES MAGNER at radaris.com
Name
Address
Phone
James Magner, age 79
122 Foote Rd, South Glastonbury, CT 06073
(860) 251-8262
James W Magner
122 Foote, Glastonbury, CT 06033
(860) 659-4690
James W Magner, age 79
122 Foote Rd, South Glastonbury, CT 06073
(860) 659-4690
James W Magner
122 Foote Rd, South Glastonbury, CT 06073
(860) 659-4690

Organization information

See more information about JAMES MAGNER at bizstanding.com

James A Magner MD

1022 Fld Dr, New Haven, CT 06525

Industry:
Medical Doctor's Office, Internist
Doing business as:
James Magner MD
Phone:
(203) 812-2588 (Phone)
Principal:
James A. Magner (Principal)

Professional information

James Arthur Magner Photo 1

James Arthur Magner, West Haven CT

Specialties:
Internal Medicine, Endocrinology and Metabolism, Endocrinology, Diabetes & Metabolism
Work:
Bayer Corp
400 Morgan Ln, West Haven, CT 06516
Education:
University of Chicago (1977)


James A Magner Photo 2

Dr. James A Magner, Woodbridge CT - MD (Doctor of Medicine)

Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
1022 Field Dr, Woodbridge 06525
Certifications:
Diabetes, Metabolism & Endocrinology, 1983, Internal Medicine, 1980
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1977
U Tex Hlth Sci Ctr
National Institutes Of Health Clinical Center


James Magner Photo 3

Formulations For Therapeutic Administration Of Thyroid Stimulating Hormone (Tsh)

US Patent:
2010004, Feb 25, 2010
Filed:
Sep 18, 2007
Appl. No.:
12/441836
Inventors:
Eliana Clark - Boylston MA, US
James Magner - Woodbridge CT, US
Jeffrey Skell - Westborough MA, US
International Classification:
A61K 38/22, A61P 5/14
US Classification:
514 5
Abstract:
This disclosure generally relates to novel formulations containing the active ingredient thyroid stimulating hormone (TSH) having modified pharmacokinetic profiles as compared to prior art formulations.